Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BREIF
March 8, 2004
- Pharma Sales to Fall Short of Forecast in FY2003: Ajinomoto
March 8, 2004
- Daiichi to Establish R&D Subsidiary in the US Aimed at FDA Applications
March 8, 2004
- The Economist Conferences
March 8, 2004
- Taiyo to Expand "Total Contract Manufacturing" Business
March 8, 2004
- BULLETIN
March 1, 2004
- Sankyo to Conduct Large-scale Clinical Study on Olmesartan
March 1, 2004
- BULLETIN
March 1, 2004
- Tanabe Receives Monkasho Approval for Human ES Cell Study
March 1, 2004
- Meropen IV Gets Remedy of Purulent Meningitis as Add. Indication
March 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 1, 2004
- Chuikyo Approves FY2004 Medical Fee Revision Proposal
March 1, 2004
- OTC NEWS IN BRIEF
March 1, 2004
- REGULATORY NEWS IN BRIEF
March 1, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 1, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 1, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 1, 2004
- JT Sees Pharma Business as "Next-generation Mainstay"
March 1, 2004
- Wishing to Keep AGR of 10-15% for Coming Years: Dr Tallarigo of Eli Lilly
March 1, 2004
- Sales of Daiichi's Coversyl Beginning to Slacken
March 1, 2004
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…